Matthew Herper

Forbes reporter covering science and medicine.

Categories
N/A
Content Types
N/A
More Information
Location|Languages
Publications

Published Content

166
Researchers Behind Spinraza Win Breakthrough Prize
forbes.comArticle
Researchers Behind Spinraza Win Breakthrough Prize
October, 17 2018
How Paul Allen Taught Me To Peel An Orange
forbes.comArticle
How Paul Allen Taught Me To Peel An Orange
October, 16 2018
A Preview Of The 2018 Forbes Healthcare Summit
forbes.comArticle
A Preview Of The 2018 Forbes Healthcare Summit
October, 10 2018
Sarepta Gene Therapy Appears To Help Fourth Boy With Duchenne Muscular Dystrophy
forbes.comArticle
Sarepta Gene Therapy Appears To Help Fourth Boy With Duchenne Muscular Dystrophy
October, 3 2018
Sarepta Gene Therapy Appears To Help Fourth Boy With Duchenne Muscular Dystrophy
forbes.comArticle
Sarepta Gene Therapy Appears To Help Fourth Boy With Duchenne Muscular Dystrophy
October, 3 2018
CRISPR-Based Drugmaker Raises $80 Million
forbes.comArticle
CRISPR-Based Drugmaker Raises $80 Million
September, 28 2018
Aiming To Revolutionize Medical Ultrasound, Butterfly Raises $250 Million At A $1.25 Billion Valuation
forbes.comArticle
Aiming To Revolutionize Medical Ultrasound, Butterfly Raises $250 Million At A $1.25 Billion Valuation
September, 27 2018
Alnylam Posts Positive Data On Second Drug, Plans FDA Meeting
forbes.comArticle
Alnylam Posts Positive Data On Second Drug, Plans FDA Meeting
September, 27 2018
In Blowout, Amarin's Fish-Oil-Derived Drug Dramatically Cuts Heart Risk In Study
forbes.comArticle
In Blowout, Amarin's Fish-Oil-Derived Drug Dramatically Cuts Heart Risk In Study
September, 24 2018
Paralyzed Patients Go From Wheelchairs To Walkers With Experimental Treatment
forbes.comArticle
Paralyzed Patients Go From Wheelchairs To Walkers With Experimental Treatment
September, 24 2018
Why Former Novartis CEO Joe Jimenez Joined A Microbiome Startup's Board
forbes.comArticle
Why Former Novartis CEO Joe Jimenez Joined A Microbiome Startup's Board
September, 21 2018
At Joe Biden's Urging, Airbnb, WeWork, And Others Commit To Help Cancer Patients
forbes.comArticle
At Joe Biden's Urging, Airbnb, WeWork, And Others Commit To Help Cancer Patients
September, 21 2018
For A New Device To Treat Maternal Bleeding, A Young Entrepreneur's Big Step Was Letting Go
forbes.comArticle
For A New Device To Treat Maternal Bleeding, A Young Entrepreneur's Big Step Was Letting Go
September, 20 2018
A $100 Million Biotech Deal Is Also A Tale Of Two Executives Facing Their Kids' Deadly Diseases
forbes.comArticle
A $100 Million Biotech Deal Is Also A Tale Of Two Executives Facing Their Kids' Deadly Diseases
September, 20 2018
If It Wanted To, The FDA Could Destroy E-Cigarette Makers
forbes.comArticle
If It Wanted To, The FDA Could Destroy E-Cigarette Makers
September, 12 2018
Semiautomatic Rifles May Make Mass Shootings Deadlier, Study Says
forbes.comArticle
Semiautomatic Rifles May Make Mass Shootings Deadlier, Study Says
September, 11 2018
How To Really Take Medical Conflicts Of Interest Seriously
forbes.comArticle
How To Really Take Medical Conflicts Of Interest Seriously
September, 10 2018
Of Vampires And The Challenges Of Longevity Drugs
forbes.comArticle
Of Vampires And The Challenges Of Longevity Drugs
September, 7 2018
Pharma Billionaire Charged With Penny Stock Fraud
forbes.comArticle
Pharma Billionaire Charged With Penny Stock Fraud
September, 7 2018
Jackie Fouse, Admired By Investors, To Become CEO Of Biotech Agios
forbes.comArticle
Jackie Fouse, Admired By Investors, To Become CEO Of Biotech Agios
September, 4 2018
Pfizer Drug Reduces Death Rate In Patients With Hearts Damaged By Protein Clumps
forbes.comArticle
Pfizer Drug Reduces Death Rate In Patients With Hearts Damaged By Protein Clumps
August, 27 2018
Esperion's Cholesterol Combo Pill Cuts Bad Cholesterol 35%
forbes.comArticle
Esperion's Cholesterol Combo Pill Cuts Bad Cholesterol 35%
August, 27 2018
The Agonizingly Slow Progress Against The Cancer That Killed Aretha Franklin
forbes.comArticle
The Agonizingly Slow Progress Against The Cancer That Killed Aretha Franklin
August, 16 2018
A Harvard Scientist Thinks He Has a Gene Test for Heart Attack Risk. He Wants to Give It Away Free.
forbes.comArticle
A Harvard Scientist Thinks He Has a Gene Test for Heart Attack Risk. He Wants to Give It Away Free.
August, 13 2018
Alnylam Prices First Gene Silencing Drug At $450,000 Per Patient, But Offers Money-Back Guarantee
forbes.comArticle
Alnylam Prices First Gene Silencing Drug At $450,000 Per Patient, But Offers Money-Back Guarantee
August, 10 2018
RegenXBio Gene Therapy Shows Early Promise Eye Disease; Cholesterol Treatment Results Mixed
forbes.comArticle
RegenXBio Gene Therapy Shows Early Promise Eye Disease; Cholesterol Treatment Results Mixed
August, 8 2018
Regeneron And Bluebird Team To Invent New Cell Therapies For Cancer
forbes.comArticle
Regeneron And Bluebird Team To Invent New Cell Therapies For Cancer
August, 6 2018
Positive Results For Ovid Drug, But Questions Remain
forbes.comArticle
Positive Results For Ovid Drug, But Questions Remain
August, 6 2018
23andMe Gets $300 Million Boost From GlaxoSmithKline To Develop New Drugs
forbes.comArticle
23andMe Gets $300 Million Boost From GlaxoSmithKline To Develop New Drugs
July, 25 2018
Biotech Entrepreneur, 29, Raises $32 Million To Use AI To Develop Drugs For Parkinson's, ALS
forbes.comArticle
Biotech Entrepreneur, 29, Raises $32 Million To Use AI To Develop Drugs For Parkinson's, ALS
July, 16 2018
Trump Phones, And Pfizer Reverses Price Hikes. But Why?
forbes.comArticle
Trump Phones, And Pfizer Reverses Price Hikes. But Why?
July, 11 2018
George Church, CRISPR Pioneer, Embraces Alternative Tech In Project To Recode A Human Genome
forbes.comArticle
George Church, CRISPR Pioneer, Embraces Alternative Tech In Project To Recode A Human Genome
May, 1 2018
This Startup Has a New CRISPR Enzyme -- And Says It Will Give It Away For Free
forbes.comArticle
This Startup Has a New CRISPR Enzyme -- And Says It Will Give It Away For Free
December, 13 2017
Scientists Could Cure Hemophilia With Gene Therapy. For Real.
forbes.comArticle
Scientists Could Cure Hemophilia With Gene Therapy. For Real.
December, 9 2017
Power Women Entrepreneurs 2015
forbes.comArticle
Power Women Entrepreneurs 2015
March, 28 2016
Top Biotech Investors On The 2016 Midas List
forbes.comArticle
Top Biotech Investors On The 2016 Midas List
March, 23 2016
Were There 30 Million Cheaters On Ashley Madison, Or 10? How Estimates Get Out Of Hand
forbes.comArticle
Were There 30 Million Cheaters On Ashley Madison, Or 10? How Estimates Get Out Of Hand
September, 1 2015
Theranos' Elizabeth Holmes And Top Executives To Reimagine Healthcare At The Forbes Healthcare Summit
forbes.comArticle
Theranos' Elizabeth Holmes And Top Executives To Reimagine Healthcare At The Forbes Healthcare Summit
August, 31 2015
Alnylam, Medicines Co. Cholesterol Shot Exceeds Expectations, Lasts 140 Days
forbes.comArticle
Alnylam, Medicines Co. Cholesterol Shot Exceeds Expectations, Lasts 140 Days
August, 30 2015
Nine Explanations For Why The FDA Is Approving Almost Every New Drug Application
forbes.comArticle
Nine Explanations For Why The FDA Is Approving Almost Every New Drug Application
August, 25 2015
Sweet Victory: Eli Lilly's Jardiance Is First Diabetes Drug To Reduce Heart Attacks And Strokes
forbes.comArticle
Sweet Victory: Eli Lilly's Jardiance Is First Diabetes Drug To Reduce Heart Attacks And Strokes
August, 20 2015
Patient Death Does Not Augur Doom, But Kite Pharma Needs To Shut Its Big Mouth
forbes.comArticle
Patient Death Does Not Augur Doom, But Kite Pharma Needs To Shut Its Big Mouth
August, 17 2015
Carly Fiorina Is Against Vaccine Mandates But She's For Them But Also Against Them
forbes.comArticle
Carly Fiorina Is Against Vaccine Mandates But She's For Them But Also Against Them
August, 14 2015
Bill Gates And 13 Other Investors Pour $120 Million Into Revolutionary Gene-Editing Startup
forbes.comArticle
Bill Gates And 13 Other Investors Pour $120 Million Into Revolutionary Gene-Editing Startup
August, 10 2015
Shire's $30 Billion Baxalta Bid Faces Big Hurdles
forbes.comArticle
Shire's $30 Billion Baxalta Bid Faces Big Hurdles
August, 4 2015
Why Pharma Must Change Its Model
forbes.comArticle
Why Pharma Must Change Its Model
July, 30 2015
The Top Drug Launches Of All Time
forbes.comArticle
The Top Drug Launches Of All Time
July, 29 2015
Regeneron's George Yancopoulos Becomes Pharma's First Billionaire R&D Chief
forbes.comArticle
Regeneron's George Yancopoulos Becomes Pharma's First Billionaire R&D Chief
July, 28 2015
Allergan: Pharma's Biggest Dealmaker Is On The Hunt Again
forbes.comArticle
Allergan: Pharma's Biggest Dealmaker Is On The Hunt Again
July, 27 2015
Allergan To Buy Antidepressant Maker For $560 Million With Hopes Of Preventing Suicides
forbes.comArticle
Allergan To Buy Antidepressant Maker For $560 Million With Hopes Of Preventing Suicides
July, 26 2015
Authorship Stats
1Sites166Projects94,560Words
About
Matthew Herper is a writer who has produced content for forbes.com
Key Phrases
Chief Executive, Drug Administration, Heart Attacks, Gene Therapy, Health Care, New York, Cancer Drug, Drug Companies, Forbes Healthcare, Healthcare Summit
© ClearVoice, Inc.